European Journal of Medicinal Chemistry p. 445 - 469 (2019)
Update date:2022-08-15
Topics:
Ge, Weizhi
Hao, Xin
Han, Fangzhi
Liu, Zhongquan
Wang, Tianpeng
Wang, Mengmeng
Chen, Ning
Ding, Yahui
Chen, Yue
Zhang, Quan
Triple-negative breast cancer (TNBC) is the most aggressive cancers with a high recurrence rate and rapidly acquired drug resistance among various breast cancer subtypes. There is no specific drug for treatment of TNBC. Discovery of therapeutic agents with unique modes of actions is urgently needed. In this study, a series of seventy parthenolide derivatives was designed, synthesized, and evaluated for their anti-TNBC activities. Compound 7d exhibited the most potent activity against different breast cancer cells with IC50 values ranging from 0.20 μM to 0.27 μM, which demonstrated 11.6- to 18.6-fold improvement comparing to that of the parent compound parthenolide with IC50 values of 2.68–4.63 μM. It is worth to note that 7d was more active than the positive control drug ADR. Moreover, compound 7d could induce apoptosis of SUM-159 cells through mitochondria pathway and cause G1 phase arrest of SUM-159 cells. These findings indicate that compound 7d deserves further studies as a lead compound for ultimate discovery of effective anti-TNBC drug.
View MoreContact:+49-4101-3053-0
Address:Waldhofstrasse 14 ,25474 Ellerbek Germany
Contact:86-21-57725962
Address:shanghai
JIAXING SUNS INTERNATIONAL TRADE CO LTD
Contact:18367306858
Address:No.123,Huixin Avenue,Huimin Dist
Jingzhou TianHe Sci&Tech Chemical Co., Ltd.
Contact:86-716-8331612
Address:Jiangjin Road, #18, High-grade technology industries development district, Jingzhou city, Hubei province
SEA BRGIHT INDUSTRY CO.,LIMITED
Contact:0086 755 8622 3990
Address:Rm 17B3,GuangCaiXinTianDi Bldg,GuiMiao Rd,NanShan District,Shenzhen,China
Doi:10.1021/acs.joc.8b00983
(2018)Doi:10.1002/anie.202004652
(2020)Doi:10.1007/BF01158481
()Doi:10.1021/jo00946a025
(1973)Doi:10.1021/acs.orglett.5b02743
(2015)Doi:10.1039/P19720002067
(1972)